Israeli attorney general orders probe into report that alleged Netanyahu's wife harassed opponents
Peru declares environmental emergency after oil spill
The strike against Amazon is over but Teamsters warn: ‘Stay tuned’
Bad Bunny announces a new album, 'Debí Tirar Más Fotos'
Column-Why US Congress restored Social Security benefits for public-sector retirees: Mark Miller
Pat Riley says the Miami Heat will not trade Jimmy Butler
‘Wicked’ will make its streaming debut on New Year’s Eve, with deleted and extended scenes
COPENHAGEN (Reuters) - Novo Nordisk has agreed to buy ocedurenone, a drug for uncontrolled hypertension with potential application in cardiovascular and kidney disease, from KBP Biosciences for up to $1.3 billion, the Danish drugmaker said on Monday.
"This deal is closely aligned with our strategic focus on expanding from our core in diabetes into other serious chronic diseases, including through novel drug modalities," Novo said in a statement.
The acquisition is expected to close before the end of this year, Novo said, adding that the deal will not impact its operating profit outlook for 2023.
Ocedurenone is an orally administered drug that is currently examined in the phase 3 trial CLARION-CKD in patients with uncontrolled hypertension and advanced chronic kidney disease, Novo said.
(Reporting by Louise Breusch Rasmussen, editing by Terje Solsvik)
